{"description":"Documents matching '\"Psychopharmacologic Drugs Advisory Committee\"' and published on or after 01/01/2026","count":16,"total_pages":1,"results":[{"title":"Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2028, expiration date.","document_number":"2026-10674","html_url":"https://www.federalregister.gov/documents/2026/05/29/2026-10674/advisory-committee-psychopharmacologic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-29/pdf/2026-10674.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10674.pdf?1779972313","publication_date":"2026-05-29","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Administration (FDA) is announcing the renewal of the <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2028, expiration date. \n \n \n DATES: \n Authority for the <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> will expire on June 4, 2026, unless the Commissioner formally"},{"title":"Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Drug Safety and Risk Management Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Drug Safety and Risk Management Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 31, 2028, expiration date.","document_number":"2026-10371","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10371/advisory-committee-drug-safety-and-risk-management-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10371.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10371.pdf?1779453911","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Product Safety Standards AC \n • Technical and Electronic"},{"title":"Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished.","document_number":"2026-14829","html_url":"https://www.federalregister.gov/documents/2026/07/23/2026-14829/advisory-committee-peripheral-and-central-nervous-system-drugs-advisory-committee-termination-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-23/pdf/2026-14829.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-14829.pdf?1784724308","publication_date":"2026-07-23","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"(Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"},{"title":"Request for Nominations for Individuals and Consumer Organizations for Advisory Committees","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committees selected without regard to race, color, national origin, religion, age, or sex.","document_number":"2026-20065","html_url":"https://www.federalregister.gov/documents/2026/10/01/2026-20065/request-for-nominations-for-individuals-and-consumer-organizations-for-advisory-committees","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20065.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20065.pdf?1790772309","publication_date":"2026-10-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"specialties \n 1—Nonvoting \n Immediately. \n \n \n Pharmacy Compounding Drugs Advisory Committee—Knowledgeable in the fields of pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties \n 1—Nonvoting \n Immediately. \n \n \n <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span>—Knowledgeable in psychopharmacology, psychiatry, epidemiology, statistics, and related specialties \n 1—Nonvoting \n Immediately. \n \n \n \n Pulmonary-Allergy Drugs Advisory Committee—Knowledgeable in the fields of pulmonary medicine, allergy, clinical immunology"},{"title":"Advisory Committee; Science Board to the Food and Drug Administration; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Science Board to the Food and Drug Administration for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 26, 2028, expiration date.","document_number":"2026-12235","html_url":"https://www.federalregister.gov/documents/2026/06/18/2026-12235/advisory-committee-science-board-to-the-food-and-drug-administration-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-18/pdf/2026-12235.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12235.pdf?1781700309","publication_date":"2026-06-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Nonprescription Drugs Advisory Committee \n Oncologic Drugs Advisory Committee \n Patient Engagement Advisory Committee \n Pediatrics Advisory Committee \n Peripheral and Central Nervous System Advisory Committee \n Pharmacy Compounding Advisory Committee \n <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n Pulmonary-Allergy Drugs Advisory Committee \n Risk Communication Advisory Committee (Administratively Inactive) \n Technical Electronic Product Radiation Safety Standards Committee \n Tobacco Products Advisory Committee \n \n 5. \n Justification that the information"},{"title":"Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Antimicrobial Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Antimicrobial Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.","document_number":"2026-20142","html_url":"https://www.federalregister.gov/documents/2026/10/01/2026-20142/advisory-committee-antimicrobial-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20142.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20142.pdf?1790712911","publication_date":"2026-10-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"},{"title":"Advisory Committee; Gastrointestinal Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Gastrointestinal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Gastrointestinal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 3, 2028, expiration date.","document_number":"2026-03587","html_url":"https://www.federalregister.gov/documents/2026/02/24/2026-03587/advisory-committee-gastrointestinal-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-24/pdf/2026-03587.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-03587.pdf?1771854307","publication_date":"2026-02-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Oncologic Drugs Advisory Committee \n \n • Patient Engagement Advisory Committee\n \n \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Product Safety Standards AC \n • Technical and Electronic"},{"title":"Advisory Committee; Pulmonary-Allergy Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Pulmonary-Allergy Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Pulmonary- Allergy Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 30, 2028, expiration date.","document_number":"2026-10410","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10410/advisory-committee-pulmonary-allergy-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10410.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10410.pdf?1779453918","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Products Safety Standards Advisory Committee \n • Tobacco Products Scientific Advisory Committee \n \n"},{"title":"Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 23, 2028, expiration date.","document_number":"2026-05313","html_url":"https://www.federalregister.gov/documents/2026/03/18/2026-05313/advisory-committee-obstetrics-reproductive-and-urologic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-18/pdf/2026-05313.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05313.pdf?1773751518","publication_date":"2026-03-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Products Safety Standards Advisory Committee \n • Tobacco"},{"title":"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16999","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16999/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16999.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16999.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Product Radiation Safety Standards Advisory Committee"},{"title":"Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Anesthetic and Analgesic Drug Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Anesthetic and Analgesic Drug Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 1, 2028, expiration date.","document_number":"2026-08125","html_url":"https://www.federalregister.gov/documents/2026/04/27/2026-08125/advisory-committee-anesthetic-and-analgesic-drug-products-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-27/pdf/2026-08125.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08125.pdf?1777034709","publication_date":"2026-04-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"},{"title":"Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.","document_number":"2026-20141","html_url":"https://www.federalregister.gov/documents/2026/10/01/2026-20141/advisory-committee-dermatologic-and-ophthalmic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20141.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20141.pdf?1790712911","publication_date":"2026-10-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"},{"title":"Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16998","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16998/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16998.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16998.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Product Radiation Safety Standards Advisory Committee"},{"title":"Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cellular, Tissue, and Gene Therapies Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 28, 2028, expiration date.","document_number":"2026-20989","html_url":"https://www.federalregister.gov/documents/2026/10/14/2026-20989/advisory-committee-cellular-tissue-and-gene-therapies-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-14/pdf/2026-20989.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20989.pdf?1791895521","publication_date":"2026-10-14","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Committee\n \n \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"},{"title":"Advisory Committee; Blood Products Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Blood Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Blood Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 13, 2028, expiration date.","document_number":"2026-09108","html_url":"https://www.federalregister.gov/documents/2026/05/07/2026-09108/advisory-committee-blood-products-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-07/pdf/2026-09108.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09108.pdf?1778071535","publication_date":"2026-05-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Oncologic Drugs Advisory Committee \n \n \n • Patient Engagement Advisory Committee \n • Pediatrics Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Pharmacy Compounding Drugs AC \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical and Electronic Product Safety Standards AC \n • Technical and Electronic"},{"title":"Advisory Committee; Oncologic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2028, expiration date.","document_number":"2026-17084","html_url":"https://www.federalregister.gov/documents/2026/08/21/2026-17084/advisory-committee-oncologic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-21/pdf/2026-17084.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-17084.pdf?1787229913","publication_date":"2026-08-21","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":" • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • <span class=\"match\">Psychopharmacologic Drugs Advisory Committee</span> \n • Pulmonary-Allergy Drugs Advisory Committee \n • Risk Communication Advisory Committee (Administratively Inactive) \n • Science Board to the Food and Drug Administration \n • Technical Electronic Product Radiation Safety Standards Committee \n • Tobacco"}]}